Phase II Bisantrene trial data published in European Journal of Haematology

On November 10, 2020 Race Oncology Limited (ASX: RAC) reported that the clinical data from the investigator initiated Phase II clinical trial of Bisantrene in relapsed and refractory Acute Myeloid Leukaemia (R/R AML), conducted at Israel’s Sheba Medical Centre has been published (Press release, Race Oncology, NOV 10, 2020, View Source [SID1234570475]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This open label, single agent trial, led by Professor Arnon Nagler, studied patients (n=10) with relapsed or refractory Acute Myeloid Leukaemia (R/R AML) who on average had failed three prior lines of treatment. Bisantrene was found to be well tolerated, and after only a single course of treatment, an overall clinical response rate of 40% was observed (ASX Announcement: June 16 2020).

The paper, entitled "A phase II study of Bisantrene in patients with relapsed/refractory acute myeloid leukemia" by Canaani et al. concludes:

"…bisantrene induced clinical responses in 4 of 10 patients with R/R AML with acceptable toxicity. Bisantrene is somewhat similar to Thiotepa and Treosulfan in that an old drug that is being now revisited gaining a lot of interest especially due to better understanding of its intracellular mechanism of action blocking FTO, a recently discovered key factor in leukomogenesis. Further studies are needed to make evidence-based conclusions regarding the candidate role of bisantrene in AML therapeutics. While interventions targeting FLT3, IDH1, IDH2, and hedgehog signalling provide new hope, traditional cytotoxic chemotherapy retains a critical role in AML patient management. We speculate that bisantrene-based chemotherapy may have its greatest applicability to patients with extramedullary disease given the marked activity here observed with leukemia cutis, chloromas, and CNS disease. Our data reveal a particularly encouraging response in this high-risk population and support additional bisantrene clinical trials in R/R AML patients."

SBP to Participate in the 11th Annual Craig-Hallum Alpha Select Conference

On November 10, 2020 Sun BioPharma, Inc. (Nasdaq:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, reported it will participate in the 11th Annual CraigHallum Alpha Select Conference to be held virtually on Tuesday, Nov 17, 2020 (Press release, Sun BioPharma, NOV 10, 2020, https://www.sunbiopharma.com/sbp-to-participate-in-the-11th-annual-craig-hallum-alpha-select-conference/?utm_source=rss&utm_medium=rss&utm_campaign=sbp-to-participate-in-the-11th-annual-craig-hallum-alpha-select-conference [SID1234570474]). Management will host one-on-one meetings with investors who are registered to attend the conference. For more information about the conference or to schedule a virtual one-on-one meeting with management, please contact your Craig-Hallum representative. Alternatively, please contact [email protected].

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About SBP-101
SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for the exocrine pancreas and pancreatic ductal adenocarcinoma. The molecule has shown signals of tumor growth inhibition in clinical studies of US and Australian metastatic pancreatic cancer patients, suggesting complementary activity with an existing FDA-approved chemotherapy regimen. In clinical studies to date, SBP-101 has not shown exacerbation of the typical chemotherapy-related adverse events of bone marrow suppression and peripheral neuropathy. The safety data and PMI profile observed in Sun BioPharma’s current clinical trial provides support for continued evaluation of the compound in a randomized clinical trial.

Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare Conference

On November 10, 2020 Theragnostics, which is developing radiopharmaceuticals for cancer treatment, reported that the company will be attending the Jefferies 2020 Virtual London Healthcare Conference taking place November 17-19, 2020 (Press release, Theragnostics, NOV 10, 2020, View Source;utm_medium=rss&utm_campaign=theragnostics-holding-1-2-1-meetings-at-jefferies-2020-virtual-london-healthcare-conference [SID1234570473]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chief Executive Officer, Greg Mullen, PhD, FRSC and Chief Operating Officer, Gareth Smith will be meeting with individual investors and participating in the breakout events.

Elicio Therapeutics Announces Poster Presentation at 2020 Society for Immunotherapy of Cancer Annual Meeting

On November 10, 2020 Elicio Therapeutics, a next generation immunotherapy company, reported virtual poster presentations for the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) Annual Meeting November 9-14, 2020 (Press release, Elicio Therapeutics, NOV 10, 2020, View Source [SID1234570472]). The presentations will update progress in two IND-ready programs demonstrating the broad application of Elicio’s Amphiphile Platform, one for a protein subunit vaccine for COVID-19; the other targeting the seven mutations commonly present in KRAS driven cancers, approximately 25% of all human solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Posters Online (access on SITC (Free SITC Whitepaper) website): November 11 to November 14, 09:00 – 17:00 EST

Poster Q&A: November 11 at 17:15 – 17:45 EST & November 13 at 16:40–17:10 EST

Poster 1 Title: Lymph node-targeted AMP-vaccine enables tumor-directed mKRAS-specific immune responses with potent polyfunctional and cytolytic activity. Abstract Number: 479

Authors: Martin Steinbuck, PhD; Lochana Seenappa, MS; PhD; Peter C. DeMuth, PhD;

Synopsis:

ELI-002 components (AMP-mKRAS peptide antigens and AMP-CpG) are effectively delivered to lymph nodes where they are efficiently delivered to innate immune cells
ELI-002 induces potent mKRAS-specific T cells after vaccination in mice; comparator vaccines composed of conventional peptides and adjuvants produce no detectable T cell responses
ELI-002-induced T cells are highly functional, producing multiple effector cytokines upon stimulation directly ex vivo
ELI-002-induced T cells demonstrate cytolytic activity against mKRAS-presenting target cells in vivo
Poster 2 Title: A lymph-node targeted amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2. Abstract Number: 723

Authors: Martin Steinbuck, PhD; Lochana Seenappa, MS; Aniela Jakubowski; Lisa K. McNeil, PhD; Christopher M. Haqq, MD, PhD;Peter C. DeMuth, PhD;

Synopsis:

ELI-005 (Spike RBD + AMP-CpG) induced highly potent T cell and antibody immunity specific to SARS-CoV-2 Spike RBD
Polyfunctional cytokine secreting T cell responses were detected directly ex vivo in blood, spleen, and lung tissues; ELI-005 generated response frequencies significantly higher than those induced by Alum or soluble CpG comparator groups
ELI-005-induced neutralizing antibody responses were observed at levels significantly higher than found in convalescent human patient samples
Vaccination with AMP-CpG in ELI-005 allowed for 10x dose reduction of RBD protein antigen without any decrease in the magnitude or functionality of induced T cell or neutralizing antibody responses
ELI-005 produced enhanced T cell and antibody responses in aged mice, exceeding those generated by Alum or soluble CpG adjuvanted vaccines
Elicio’s posters will also be made available on the News section of Elicio’s website.

About the Amphiphile Platform

The Elicio Amphiphile platform enables precise targeting and delivery of immunogens and cell-therapy activators directly to the lymphatic system, the "brain center" of the immune response, to significantly amplify and enhance the body’s own system of defenses, defeat solid and hematologic cancers, and prevent their recurrence. Once in the lymph nodes, Amphiphile immunotherapies are taken up by antigen presenting cells (APC’s) to orchestrate signaling to natural or engineered immune cells in order to maximize therapeutic immune responses to disease. This strategy has been used to improve the activity of immunostimulatory agents, antigens, adjuvants, and cell-therapies that generate little to no response when used in the conventional forms. By precisely targeting these immunotherapies to the lymph nodes, Amphiphiles can unlock their full potential to generate and amplify anti-tumor immune responses. This substantially enhanced anti-tumor functionality and long-term protective memory may someday unlock the full potential of the immune response to eliminate cancer.

Varian Medical Systems Invests in COTA, Inc. to Help Drive Faster, More Accurate Data-Driven Cancer Care

On November 10, 2020 Varian (NYSE: VAR) reported a new $10M investment and collaboration agreement with COTA, Inc., a Boston-based curator of clinical data in oncology (Press release, Varian Medical Systems, NOV 10, 2020, View Source [SID1234570471]). Both companies will work together to empower cancer clinics with data analytics and decision support tools, using real-world evidence to help guide clinical and operational decisions as well as drive more cost-effective care.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, Varian will offer its customers access to COTA’s oncology real-world analytics and data curation services, which aggregate fragmented and often incomplete electronic health record (EHR) data to tease out meaningful insights. At the same time, COTA will help Varian create better Intelligent Cancer Care tools for decision support using real world evidence.

Varian, through its Intelligent Cancer Care initiative, is working to create a technology ecosystem that connects clinicians and patients into a global continuously learning system that is fueled by information, driven by collaboration and accelerated by artificial intelligence (AI) to improve outcomes.

"This agreement with COTA represents a huge win for our two companies, and also for oncology care providers and researchers," said Corey Zankowski, Senior Vice President, Oncology Software Solutions. "We believe COTA’s proprietary technology, advanced analytics, and deep expertise in organizing complex data will make a significant step toward realizing the goals of Intelligent Cancer Care," Zankowski said.

"We are excited to partner with Varian to advance our shared goal of improving outcomes for cancer patients," said Mike Doyle, CEO of COTA. "This collaboration allows Varian to leverage our expertise using oncology real-world data while providing COTA with new capital to expand our work with life science companies around the globe."

Varian made two prior investments in COTA earlier this year. This latest investment brings the total amount invested to $20M, in the form of a convertible loan with an option to acquire the company at a future date.